San Francisco Bay Area Biometrics Consulting
Request a Consultation Pharma Recruiting  Contact Us Iphone  925-320-7600 
San Francisco Bay Area Biometrics Consulting

Are Trial Design Domains optional in a CDISC-compliant e-submission to FDA? by Peng Yang

B2ap3 Large FDA Conformance Guide 3.1


On August 5, 2016, FDA released a new version of the Study Data Technical Conformance Guide version 3.1 (Guide).  This Guide provides technical specifications, recommendations, and general considerations on how to submit standardized electronic study data using FDA-supported data standards located in the FDA Data Standards Catalog (Standards Catalog).  As always, anyone who is going to be involved in submission data preparation should study the entire Guide thoroughly. We would like to discuss one important issue that is often overlooked, which is the decision to include Trial Design Domains in an e-submission.

Emphasizing Trial Design Model in SDTM and SEND

FDA emphasizes the importance of Trial Design Model (TDM) which includes Trial Arms, Trial Elements, Trial Visit, Trial Inclusion/Exclusion Criteria, Trial Summary and Trial Disease Assessment.   FDA strongly recommends that sponsors should include Trial Summary (TS) even for legacy studies.  What is the unique about TS is that the study start date (SSTDTC in TS.TSPARMCD) in the TS domain will determine whether a given study needs to use a particular data standards as specified in Standards Catalog.  The requirement for providing TS domain for NDA/BLA was also made clear by FDA at the 2016 FDA/PHUSE Computational Science Symposium (CSS).  Therefore, it is a must-have, not a nice-to-have item. In SEND submission, all the Trial Design domains should be included as well.

Data for building Trial Design Domains may not in the EDC raw data

We have noticed that one common reason for people to push back on creating TDM is that the source data are not in the EDC database. Some are actually from protocol and sometimes it is unclear whose responsibilities it is to build these domains.   At Clindata Insight, when we review CRO deliverables as part of our CRO Oversight consulting service, we pay special attention to check the deliverables against FDA’s requirements such as what is included in this Guide.   We strongly urge sponsor companies to use this Guide to evaluate their CRO’s knowledge of supporting CDISC compliant submission. A quality vendor should have thorough understanding of the Guide and provide solid adherence to the Guide.

If you have any questions regarding preparing standardized data for your FDA submission, please contact us at .

#NDA #BLA #CDISC #SDTM #SEND #submission

What Kevin Durant teaches us about talents in Biom...
Webinar video: How Will the New FDA Technical Reje...

Related Posts

Ready to Get Started?

Schedule a No Obligation Consultation with a Clindata Insight Representative Today

14 February 2017
Berkeley Statistics Annual Research Symposium (BSTARS) The Berkeley Statistics Annual Research Sympo...
26 August 2016
  On August 5, 2016, FDA released a new version of the Study Data Technical Conformance Guide v...
19 January 2017
Clindata is proud to sponsor the next SF Bay Area CDISC meeting being held on February 9, 2017 at 12...
14 February 2017
The Computational Sciences Symposium (CSS) will be celebrating its 6th annual event and has establis...

Copyright © 2016   Clindata Insight Inc.   All Rights Reserved

Clindata Insight Inc, provides equal employment opportunities (EEO) to all applicants for employment without regard to race, color, religion, sex, national orgin, age, disability or genetics.  In addition to federal law requirements Clindata Insight complies with applicable state and local laws governing non discrimination in employment.

        (925) 320-7600